Skip to main content
. 2021 May 19;59(1):617–626. doi: 10.1080/13880209.2021.1923759

Figure 1.

Figure 1.

Lappaol F (LAF) inhibited viability of human cancer cells. (A) Structure of LAF. (B-E). Human cancer cells (HeLa, MDA-MB-231, SW480 and PC3) were treated with LAF (0, 10, 25, 50 or 75 µmol/L) for 24, 48 or 72 h. Cell viability was assessed by sulforhodamine B assay. All data are expressed as the mean ± SD (n = 5). **p < 0.01, significantly different from the control without LAF treatment.IC50: half inhibitory concentration.